The EuroMyositis Registry: An International Collaborative Tool to Facilitate Myositis Research

Supplementary Appendices:

Supplementary Appendix A.................................................................................................................................................................2
  The EuroMyositis Registry.................................................................................................................................................................2
    Background ..........................................................................................................................................................................................2
    Current capabilities...........................................................................................................................................................................5
    Outputs...........................................................................................................................................................................................5
    Future developments.......................................................................................................................................................................6

Supplementary Appendix B.............................................................................................................................................................9
  EuroMyositis Registry Definitions.....................................................................................................................................................9
  Summary of Case Reclassification ....................................................................................................................................................13
  References.........................................................................................................................................................................................15
Supplementary Appendix A

The EuroMyositis Registry

Background

EuroMyositis (https://euromyositis.eu/) is the largest IIM disease registry. Three centres took the initiative to create the Registry: The University of Manchester (Manchester, UK), Rheumatology Institute (Prague, Czech Republic) and Karolinska Institutet (Stockholm, Sweden). In the UK, it evolved from data captured as part of the Adult Onset Myositis Immunogenetic Collaboration (AOMIC). This was set up in 1999 and later became the UK Myositis Network (UKMYONET). In Sweden, a similar project called SweMyoNet was established in 2003 and in the Czech Republic, the myositis section of National Registry of Inflammatory Rheumatic Diseases, formed in 2002, was used as the basis for data entry into EuroMyositis. Records from these separate datasets were entered into the EuroMyositis Registry in 2003, using the criteria from Bohan and Peter as inclusion criteria.

A Delphi process and consensus discussion among Rheumatology and Neurology experts from these centres led to creation of uniform data collection pro-forma. The EuroMyositis Registry also incorporates the International Myositis Assessment & Clinical Studies Group (IMACS) disease activity and disease damage core set measures [1,2].

To facilitate data input, storage and access, a web-based interface was created using the Plone platform (an open source Python-based content management system) with extensions shared with the DANBIO-IT-platform (https://danbio-online.dk). All data are encrypted and stored on secure and automatically backed-up servers approved by authorities in Denmark. The Registry can be accessed from any computer with internet access (Supplementary Appendix Figure 1).
The EuroMyositis registry now includes 20 centres in 16 countries (correct as of 25/08/2016). A summary of the country of origin of patients included in our study is shown in Supplementary Table 1 and Supplementary Appendix Figure 2. Several other centres are currently involved in the application and set-up process. Ethical approvals are required at each centre where the registry is implemented and informed consent is obtained from all included patients. The exact structures used to collect data vary from country to country. For example, in the UK, the project is coordinated from the University of Manchester, but 63 individual centres contribute data.

Each centre may only access their individual dataset by default. This can be done on an individual patient basis using the website, often useful during clinical consultations, or by downloading a file containing the whole dataset in a spreadsheet format. Most data are input manually, but there are facilities for uploads of data to the registry en-masse and the ability to synchronise with other systems, including electronic health records.

Several centres outside Europe are now participating, increasing ethnic variety within the dataset which initially consisted principally of European Caucasians. In addition, the Registry
has been recently expanded to include a section relating specifically to JDM, although this data was not analysed as part of this study.

The EuroMyositis administrative structure includes a steering committee and affiliated external IT-expert. The steering committee meets 3-4 times a year to discuss ongoing development of the registry, consideration of requests for use in new centres and consideration of formal requests to use the data in specific research studies, for which specific ethical approval from recruited patients has been obtained.

Supplementary Appendix Figure 2: Map indicating case contributions to the EuroMyositis Registry per country included in this study. Depth of shading indicates the total number of patients contributed from each country (see key).
Current capabilities
Within the Registry, each patient record is arranged into two main sections. Firstly, a ‘core’
dataset includes diagnostic details, associated investigation results, demographic information
and baseline clinical characteristics. Autoantibody results and muscle biopsy findings can be
included. Secondly, ‘per visit’ data can then be added for each patient (see Supplementary
Appendix Table 1 for per country contributions to this section of the Registry). This includes
clinical outcome measures as well as medication prescriptions, which can be updated
longitudinally. Data added to this section also populates a patient ‘scoreboard’ that summarises
clinical outcome measures over time (Supplementary Appendix Figure 3) and can be used in the
clinical setting to obtain a snapshot of disease activity and help facilitate discussions with
patients about their progress.

Supplementary Appendix Figure 3: A sample scoreboard for a patient with DM.
Serial clinical outcome measures are summarised.

Outputs
The benefits of a collaborative approach to rare disease research are increasingly being realised.
For example, the largest genetic study in IIM was recently completed, largely using the
EuroMyositis registry for case ascertainment and collection of clinical details [3]. In this study,
the Human Leucocyte Antigen (HLA) region and PTPN22 gene reached genome wide
significance and distinct differences between disease subgroups were identified. Further work
is ongoing, in particular a subgroup analysis focussing on patients with IBM and interactions
between HLA alleles and serotype [4]. This study built on previous work using the precursors to
EuroMyositis in the UK (AOMIC and UKMYONET), where a number of important genetic [5,6] and serological [7] IIM associations were demonstrated, often in collaboration with others. In Mexico, analysis of patient data held within the EuroMyositis registry showed that possession of the \textit{ACTN3} 577X allele appeared to increase the risk of developing IIM [8].

A number of projects have focussed on the elucidation of serological associations with IIM subtypes and certain clinical features. This includes recent work examining the rate of multiple MSA positivity in IIM [9] and a collaborative effort between the UK, The Netherlands, France and Sweden which has analysed the clinical implications of anti-CN-1a autoantibody positivity in patients with IBM [10]. In Mexico, the EuroMyositis registry has been used to characterise patients with IIM that have anti-Mi2 or anti-TIF1-gamma autoantibodies [11]. Data from the same group contributed to research regarding the implications of anti-TIF1-beta autoantibodies in those with DM [12]. Other ongoing projects include an analysis of factors predicting disease progression in patients with PM and DM which is being coordinated from Switzerland and an analysis of long term outcomes in childhood myositis which is being coordinated from the UK. This is already being implemented in the UK, where registry data is linked to nationally orchestrated morbidity and mortality data held by NHS Digital (formerly the Health and Social Care Information Service). This has facilitated investigations of the link between serological profile and mortality in cancer and non-cancer associated IIM [13].

**Future developments**

The EuroMyositis registry is currently undergoing modification to support the introduction of Fast Health Interoperability Resources (FHIR). FHIR is an emerging IT standard which facilitates exchange of health data by using agreed methods of describing data in different systems. This permits easier interoperability of IT systems and will support more widespread integration of the EuroMyositis registry with local electronic health records, without the requirement for bespoke synchronisation solutions. As such, the collection of routinely obtained data associated with the management of patients with IIM can automatically populate the registry avoiding the need for duplication and manual data input between different systems. Furthermore, linking to external systems provides a powerful method of investigating links between IIM and other factors such as the occurrence of comorbidities (including cancer) and mortality.

The EuroMyositis registry and underlying data storage platform is also integral to the UK Medical Research Council funded ‘Prospective Cohort Study in Myositis’ (MYOPROSP - \url{https://clinicaltrials.gov/ct2/show/NCT02468895}) and the Swedish quality of care register (SRO). Both studies are collecting standardised longitudinal data regarding national inception...
cohorts of patients with IIM. In the future there will also be an increasing emphasis on collection of longitudinal patient reported outcome measures (PROMs). These data can be input directly into the registry by the patient using a smartphone 'App' or other device (including 'wearable tech'). In addition, the Registry is being updated to employ more recently defined diagnostic/classification criteria and to harmonise data collection between the EuroMyositis Registry and other IIM registries.
**Supplementary Appendix Table 1:** Contributions to the EuroMyositis Registry per country.

<table>
<thead>
<tr>
<th>Diagnosis Appendix A</th>
<th>Belgium n (%)</th>
<th>China n (%)</th>
<th>Czech Republic n (%)</th>
<th>Hungary n (%)</th>
<th>Italy n (%)</th>
<th>Mexico n (%)</th>
<th>Norway n (%)</th>
<th>Sweden n (%)</th>
<th>Switzerland n (%)</th>
<th>United Kingdom n (%)</th>
<th>Vietnam n (%)</th>
<th>Total n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dermatomyositis</td>
<td>3 (7)</td>
<td>48 (46)</td>
<td>158 (40)</td>
<td>126 (28)</td>
<td>30 (38)</td>
<td>58 (62)</td>
<td>26 (29)</td>
<td>87 (24)</td>
<td>20 (39)</td>
<td>334 (27)</td>
<td>59 (39)</td>
<td>949 (31)</td>
</tr>
<tr>
<td>Polymyositis</td>
<td>2 (5)</td>
<td>20 (19)</td>
<td>75 (19)</td>
<td>273 (60)</td>
<td>30 (38)</td>
<td>23 (25)</td>
<td>12 (13)</td>
<td>57 (16)</td>
<td>9 (18)</td>
<td>220 (18)</td>
<td>92 (61)</td>
<td>813 (27)</td>
</tr>
<tr>
<td>Anti-synthetase Syndrome</td>
<td>2 (5)</td>
<td>15 (14)</td>
<td>74 (19)</td>
<td>21 (5)</td>
<td>7 (9)</td>
<td>5 (5)</td>
<td>34 (37)</td>
<td>73 (20)</td>
<td>15 (29)</td>
<td>266 (21)</td>
<td>0 (0)</td>
<td>512 (17)</td>
</tr>
<tr>
<td>Connective tissue disease-overlap myositis</td>
<td>6 (14)</td>
<td>11 (11)</td>
<td>45 (12)</td>
<td>12 (3)</td>
<td>10 (13)</td>
<td>0 (0)</td>
<td>10 (11)</td>
<td>67 (19)</td>
<td>2 (4)</td>
<td>195 (16)</td>
<td>0 (0)</td>
<td>358 (12)*</td>
</tr>
<tr>
<td>Inclusion Body Myositis</td>
<td>11 (25)</td>
<td>0 (0)</td>
<td>7 (2)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>2 (2)</td>
<td>51 (14)</td>
<td>1 (2)</td>
<td>168 (14)</td>
<td>0 (0)</td>
<td>240 (8)</td>
<td></td>
</tr>
<tr>
<td>Immune-Mediated Necrotising Myopathy</td>
<td>20 (46)</td>
<td>2 (2)</td>
<td>23 (6)</td>
<td>3 (1)</td>
<td>1 (1)</td>
<td>2 (2)</td>
<td>3 (3)</td>
<td>5 (1)</td>
<td>3 (6)</td>
<td>43 (4)</td>
<td>0 (0)</td>
<td>105 (3)</td>
</tr>
<tr>
<td>Juvenile Dermatomyositis</td>
<td>0 (0)</td>
<td>8 (8)</td>
<td>11 (3)</td>
<td>21 (5)</td>
<td>2 (3)</td>
<td>6 (6)</td>
<td>4 (4)</td>
<td>18 (5)</td>
<td>1 (2)</td>
<td>19 (2)</td>
<td>0 (0)</td>
<td>90 (3)</td>
</tr>
<tr>
<td><strong>Total</strong> n (%)</td>
<td>44 (100)</td>
<td>104 (100)</td>
<td>393 (13)</td>
<td>456 (15)</td>
<td>80 (3)</td>
<td>94 (3)</td>
<td>358 (12)</td>
<td>51 (2)</td>
<td>1245 (41)</td>
<td>151 (5)</td>
<td>3067 (100)</td>
<td></td>
</tr>
</tbody>
</table>

Note that some countries have more than one centre.

*Associated connective tissue disease (CTD): Systemic sclerosis (39%, 141/358), Sjögrens syndrome (15%, 54/358), Mixed connective tissue disease (15%, 52/358), Rheumatoid arthritis (9%, 32/358), Systemic lupus erythematosus (9%, 32/358), Other (13%, 47/358).
Supplementary Appendix B

EuroMyositis Registry Definitions

**Diagnostic criteria**

PM, DM and JDM

Patients with PM, DM or JDM met the Bohan and Peter probable or definite diagnostic criteria [14,15]:

1. Symmetrical proximal muscle weakness.

2. Elevation of the serum enzymes, especially creatine phosphokinase, aldolase, aspartate aminotransferase, alanine aminotransferase and lactate dehydrogenase.

3. Abnormal electromyogram with myopathic motor unit potentials, fibrillations, positive sharp waves, increased insertional irritability and spontaneous bizarre high frequency discharges.

4. Muscle biopsy evidence of necrosis, phagocytosis, regeneration, degeneration, perifascicular atrophy, and an interstitial inflammatory infiltrate.

5. Typical skin rash of DM.

Definite polymyositis: criteria 1-4, probable polymyositis 3 of criteria 1-4

Definite dermatomyositis: criterion 5 and 3 of criteria 1-4, probable dermatomyositis criterion 5 and 2 of criteria 1-4.

**Exclusion criteria for PM, DM and JDM**

The EuroMyositis Registry includes the following additional condition regarding these criteria:

> The application of these criteria assumes that known infectious, toxic, metabolic, dystrophic, or endocrine myopathies have been excluded by appropriate evaluations.

and specifically lists the following exclusion criteria:

1. Evidence of central or peripheral neurologic disease, including motor-neuron disorders with fasciculations or long-tract signs, sensory changes, decreased nerve conduction times, and fiber-type atrophy and grouping on muscle biopsy.
2. Muscle weakness with a slowly progressive, unremitting course and positive family history or calf enlargement to suggest muscular dystrophy.

3. Biopsy evidence of granulomatous myositis such as with sarcoidosis.

4. Infections, including trichinosis, schistosomiasis, trypanosomiasis, staphylococcosis and toxoplasmosis.

5. Recent use of various drugs and toxins, such as clofibrate and alcohol.

6. Rhabdomyolysis as manifested by gross myoglobinuria related to strenuous exercise, infections, crush injuries, occlusion of major limb arteries, prolonged coma or convulsions, high voltage accidents, heat stroke, the malignant-hyperpyrexia syndrome, and envenomation by certain sea snakes.

7. Metabolic disorders such as McArdle’s syndrome.

8. Endocrinopathies such as thyrotoxicosis, myxedema, hyperparathyroidism, hypoparathyroidism, diabetes mellitus, or Cushing’s syndrome.

9. Myasthenia gravis with response to cholinergics, sensitivity to d-tubocurarine, and decremental response to repetitive nerve stimulation.

10. Myositis after influenza and rubella infections, vaccination for rubella, the use of penicillamine, multicentric reticulohistiocytosis, giant-cell myositis, atheromatous microemboli, and carcinomatous thromboembolization with muscle necrosis.

Anti-synthetase syndrome

Cases in the EuroMyositis Registry can be assigned a diagnosis of anti-synthetase syndrome (ASS) by the recruiting clinician if:

“Clinical features of anti-synthetase syndrome are present together with an anti-synthetase antibody. Clinical features of anti-synthetase syndrome are: myositis, arthritis, interstitial lung disease, mechanic’s hands, Raynaud’s phenomenon, fever. The minimum for entering “yes” is the presence of anti-synthetase antibody and one clinical feature.”

It should be noted that this definition is consistent with the ASS classification criteria proposed by Conners et al that we applied to cases with PM, DM, JDM or CTD-overlap myositis. We undertook retrospective re-classification due to the fact that until recently, the results of several anti-synthetase autoantibody (ASA) results (particularly for the more novel ASAs) may not have been available to the recruiting clinician at the time of including a case in the EuroMyositis Registry.
Inclusion body myositis
IBM cases must meet either the Medical Research Council, Griggs et al, or European Neuromuscular Centre (ENMC) diagnostic criteria.[16–18]

Recent analysis of the competing IBM diagnostic criteria has suggested that whilst the differing criteria have wide-ranging sensitivities, the specificities are uniformly high.[19] Thus, we allowed the use of these different diagnostic criteria for IBM in our analysis to help improve sensitivity.

Connective tissue disease overlap myositis
The following diagnostic criteria were used for defining connective tissue diseases:

2. Systemic sclerosis: American Rheumatism Association.[21]
3. Rheumatoid arthritis: Arnett et al.[22]

Immune mediated necrotising myositis
Patients otherwise meeting the criteria for PM but with necrotic muscle fibres (in the absence of florid inflammation) as the predominant histological feature.

Clinically amyopathic-DM (CADM)
CADM is defined as a rare group of the IIM spectrum, in patients who have classic cutaneous findings confirmed by skin biopsy, in the absence of clinical, laboratory, or histologic evidence of myositis after at least 2 years of follow up.[25]

Other features

Cancer
Any malignancy regardless of whether considered as being “myositis associated” is recorded. Local practices for malignancy screening will vary from centre to centre.

Malignancy data presented in the attached manuscript is accurate up to July 2017.

Cardiac involvement related to the IIM disease process:

- Pericarditis: Inflammation of the pericardium defined clinically or by electrocardiogram (ECG) or echocardiogram
- Myocarditis: Inflammation of the myocardium defined clinically or with echocardiographic or other objective evidence
- Arrhythmia: clinical or ECG evidence of irregular heart beat
• Sinus tachycardia: resting heart rate > 100 beats per minute in an adult patient or greater than upper limit of age-appropriate normal value in a pediatric patient

Myositis-associated interstitial lung disease
  • Radiologic (chest x-ray or chest CT scan) documentation of inflammation or scarring (fibrosis) of the parenchyma of the lung, and
  • Abnormal PFT attributable to inflammatory process or pulmonary fibrosis.

Antibody status
The technique used for testing of autoantibodies was dependent upon local practice. The EuroMyositis Registry includes the following data regarding the methods used for determination of antibody status: Of the 1,951 cases with any antibody data available, 1,412 (72%) were determined by immunoprecipitation, 159 (8%) by ELISA and 84 (4%) by line blot. For 296 (15%) cases, the method for determining antibody status is not known.
Summary of Case Reclassification

We undertook a process of retrospective case reclassification to reflect the growing importance placed on serotype in determining classification. Patients recruited to the Registry prior to these developments may have been misclassified according to our current understanding. No new antibody testing or biopsy evaluations were performed as part of this study, but we did make use of information that may not have been available to clinicians at the time of patient recruitment. Details are included below:

1. Raw data regarding idiopathic inflammatory myopathy (IIM) cases downloaded. Cases with no recorded diagnosis excluded. Remaining cases included statin related myotoxicity (SRM 1-6), clinically amyopathic dermatomyositis (CADM), dermatomyositis (DM), inclusion body myositis (IBM), “unspecified myositis”, juvenile dermatomyositis (JDM), juvenile polymyositis (JPM), polymyositis (PM) and "pure" anti-synthetase syndrome (i.e. no other IIM subtype selected).

2. Cases of PM, DM, JDM or unspecified myositis with a co-existing connective tissue disease (CTD) meeting relevant diagnostic criteria* were reclassified as CTD-overlap myositis

3. Any case meeting criteria for anti-synthetase syndrome (ASS)*, either alone (“pure” ASS) or in combination with another IIM subtype, according to recruiting clinician were reclassified as ASS

4. Cases originally classified as PM, DM, CADM, JDM and cases assigned to the CTD-overlap myositis category were reclassified as ASS if they met criteria suggested by Connors et al.* / **

5. Remaining cases with ADM were reclassified as DM

6. Cases with SRM6 re-classified as immune mediated necrotising myopathy (IMNM). Remaining cases of SRM (SRM1-5), and cases of PM, where the patient also had anti-HMGCR autoantibodies were reclassified as IMNM

7. Cases of PM with anti-SRP or anti-HMGCR autoantibodies reclassified as IMNM

8. Remaining cases of SRM1-5, unspecified myositis, or JPM were removed from the analysis

9. Cases of DM & JDM excluded where confirmation could not be found that a DM-associated rash was present

10. Cases of PM, IBM, IMNM excluded if presence of DM-associated rash recorded

*See EuroMyositis Registry Definitions section of Supplementary Appendix B for full details of definitions. **Note that this did not include any patients from the CTD-overlap myositis group that were originally classified as “unspecified myositis”.

Supplementary Appendix B
3,487 patients in initial download

3,170 cases

317 - No diagnosis recorded - removed

3,170 cases

317 - No diagnosis recorded - removed

28 - Statin related myotoxicity

42 - Amyopathic dermatomyositis

1,159 - Dermatomyositis

244 - Inclusion Body Myositis

38 - Unspecified Myositis

97 - Juvenile Dermatomyositis

6 - Juvenile Polymyositis

42 - Immune Mediated Necrotising Myopathy

1,454 - Polymyositis

60 - Anti-synthetase Syndrome

Initial Diagnosis

Diagnostic Re-classifications

Final Diagnosis

358 – Connective Tissue Disease*

949 - Dermatomyositis

240 – Inclusion Body Myositis

90 – Juvenile Dermatomyositis

105 – Immune Mediated Necrotising Myopathy

813 - Polymyositis

512 – Anti-synthetase Syndrome

*Excludes 41 patients retrospectively reclassified as Anti-synthetase Syndrome and analysed as ASS, rather than with the CTD-overlap group. Subtype classifications are mutually exclusive. “Anti-synthetase Syndrome Recorded” implies that the presence of Anti-synthetase Syndrome was already flagged in the Registry against cases with other IIM subtypes. “Anti-synthetase Syndrome criteria met retrospectively” implies that we were able to reclassify the case as Anti-synthetase Syndrome using criteria proposed by Connors et al with the information available in the Registry.
† See accompanying explanations for exclusion reasons
References


